Image
user avatar
ASN Publications
@asnpublications
Showcasing the latest in kidney care, research, and innovation. Follow for updates from ASN publications, including JASN, CJASN, Kidney360, and Kidney News.
Washington, DC
bit.ly/JnlPublish
Joined August 2014
1,649
Following
32.8K
Followers
  • Pinned
    user avatar
    ASN Publications
    @asnpublications
    Mar 9
    ASN Kidney Health Guidance is produced to encourage high-quality, patient-centered care across the spectrum of kidney health, from screening and early detection through palliative care. Check out the full collection: bit.ly/JASNKHG
    Image
    1.8K
  • user avatar
    ASN Publications
    @asnpublications
    Jan 6, 2023
    SGLT2 inhibitors are now embedded in clinical practice guidelines to slow the progression of CKD in patients with and without diabetes mellitus. This Review discusses the kidney-protective effects of SGLT2 inhibitors bit.ly/CJN09380822wk
    Mechanism of glucose transport in the proximal tubule and effects of sodium-glucose cotransporter 2 (SGLT2) inhibition on the tubuloglomerular feedback mechanism and transport of uric acid and phosphate.
    36K
  • user avatar
    ASN Publications
    @asnpublications
    Oct 11, 2023
    Combination diuretic therapy is a widely applied strategy to counter renal sodium avidity. This Review discusses the results of the key studies on combination diuretic therapy in the setting of acute heart failure and their findings bit.ly/CJASN0188 @AmirKazory
    The sites of action, family of medications, and clinical trials exploring combination diuretic therapy for acute heart failure. TACTICS-HF and SECRET of CHF are refs. 70 and 71, respectively. AQP, aquaporin; CA, carbonic anhydrase; DIURESIS-CHF, Diamox to Increase the Urinary Excretion of Sodium: an Investigational Study in Congestive Heart Failure; EMPAG-HF, Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure; EMPULSE, Empagliflozin in Patients Hospitalized for Acute Heart Failure; ENaC, epithelial sodium channel; NCC, sodium-chloride cotransporter; NHE3, sodium:hydrogen exchanger 3; V2R, vasopressin-2 receptor.
    48K
  • user avatar
    ASN Publications
    @asnpublications
    May 20, 2022
    AKI is a syndrome that is often multifactorial, especially in the hospitalized patient. This Review discusses the pathophysiology of three etiologies that cause AKI: kidney hypoperfusion, abdominal compartment syndrome, & urinary tract obstruction bit.ly/CJN15341121
    The complex multiorgan pathophysiology of abdominal compartment syndrome.
  • user avatar
    ASN Publications
    @asnpublications
    Nov 17, 2023
    The benefits of SGLT2 inhibitors in patients with CKD have been well established in major clinical trials. This Perspective examines if SGLT2 inhibitors are effective & safe in patients with severe CKD, dialysis, or kidney transplantation bit.ly/CJASN0221 @StefanPBerger
    Potential cardiorenal protective mechanisms for SGLT inhibition mediated via tubular SGLT2 and via mechanisms working direct on the heart and the kidney. NHE-1, sodium–hydrogen exchange 1; SGLT2, sodium‐glucose cotransporter‐2. Adapted from Udell JA, Jones WS, Petrie MC, et al. Sodium glucose cotransporter-2 inhibition for acute myocardial infarction: JACC review topic of the week. J Am Coll Cardiol. 2022;79(20): 2058–2068.
    49K
  • user avatar
    ASN Publications
    @asnpublications
    Sep 15, 2025
    Lupus nephritis is seeing more enriching immunotherapies, but important unmet needs remain. In this #ASNCJASN article: authors detail how to focus on histological signs of immunological activity triggering immunotherapy vs signs of kidney injury requiring care for CKD.
    Image
    16K
  • user avatar
    ASN Publications
    @asnpublications
    Oct 21, 2022
    SGLT2 inhibitors are a critical part of clinical practice guidelines for the management of patients with cardiovascular disease with and without diabetes. This Review discusses the mechanisms by which they act and the potential changes in kidney function bit.ly/CJN09380822
    SGLT2 inhibition has favorable effects on perirenal fat.
  • user avatar
    ASN Publications
    @asnpublications
    Oct 11, 2022
    SGLT2 inhibitors have become an integral part of clinical practice guidelines to slow CKD progression. This Review examines the mechanisms by which this class of compounds provide kidney protection and how they impact various aspects of kidney homeostasis bit.ly/CJN09380822
    Mechanism of glucose transport in the proximal tubule and effects of SGLT2 inhibition on the tubuloglomerular feedback mechanism and transport of uric acid and phosphate.
  • user avatar
    ASN Publications
    @asnpublications
    Jul 31, 2023
    The cardiorenal syndrome refers to a group of complex, bidirectional pathophysiological pathways involving dysfunction in both the heart and kidney. This Review focuses on the cardiorenal syndrome encountered in the hospital setting bit.ly/CJASN064
    Proposed pathophysiological pathways leading to the cardiorenal syndrome and its complications. The inciting event is usually an acute decompensation of heart failure. This may lead to either arterial underfilling or venous congestion as mediators that promote neurohormonal activity, inflammation, and endothelial dysfunction. In combination, these pathways lead to reductions in glomerular filtration rate. Complications include sodium avidity and fluid retention, reduced kidney clearance, and endocrine function, all of which further perpetuate the pathophysiology. HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
    25K
  • user avatar
    ASN Publications
    @asnpublications
    Jan 14, 2022
    The KDIGO 2021 Clinical Practice Guideline for the Management of BP in CKD includes new recommendations on BP management for individuals with non-dialysis CKD. This Kidney Case Conference: How I Treat article presents a case that incorporates these updates bit.ly/CJN13040921
    Image